$CYRX

Mandalam Ramkumar sold $358K of CYRX

Mandalam Ramkumar sold 23,214 shares of Cryoport, Inc. (CYRX) at $15.44 ($0.36M total) on 2026-06-08.

Original reporting
SEC EDGAR · Mandalam Ramkumar
Published Jun 9, 2026, 1:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CYRX
Neutral
high confidence
Mentioned
$CYRX
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYRXNeutralLow
01

Why it matters

This adds a fresh datapoint on director selling activity (23,214 shares sold), but it does not introduce new company fundamentals, guidance, or regulatory/contract developments.

02

Market read

Traders may monitor CYRX insider activity, but the disclosure alone is unlikely to drive a sustained repricing without corroborating fundamental catalysts.

03

What to watch

The article provides only the sale details; it does not include context on total insider holdings, prior sales cadence, or any concurrent company-specific news.

Relevance 4/10Novelty 6/10Timing: filed 2026-06-08 (after-hours)

Background

The article is an SEC Form 4 insider transaction disclosure for Cryoport, Inc. (CYRX).

Company-level read

Ticker impact

$CYRXNeutralHigh confidence
Context

Cryoport director Mandalam Ramkumar filed an open-market sale of 23,214 shares at $15.4412 on 2026-06-08 (Form 4).

Expected impact

Low near-term impact; any effect is likely short-lived and outweighed by broader company fundamentals.

Evidence & confidence

The filing is a director open-market sale with no 10b5-1 plan stated and no new operating/financial information disclosed in the text.

Market effects

Minimal; single-company insider transaction without sector-wide read-across.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity/tax needs; without a stated 10b5-1 plan, the sale still may not reflect bearish fundamentals.

Key entities

  • Cryoport, Inc.

    Subject of the Form 4 insider transaction disclosure (CYRX).

  • Mandalam Ramkumar

    Director who sold 23,214 shares in an open-market transaction.

Related articles

$CYRXMed

Cryoport, Inc. (CYRX): Results of Operations and Financial Condition

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622464d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 2